



## **New Insulin Sensitizers Produce Differentiation of Brown-like Adipose Cells from a Subcutaneous Fat Depot and Increase Secretion of Adiponectin *in vitro***

William G. McDonald, Serena L. Cole, Danielle D. Holewa, Angela S. Brightwell-Conrad, Peter K. Harris, Jerry R. Colca, and Rolf F. Kletzien.

*Metabolic Solutions Development Company, Kalamazoo, USA.*



47th EASD Annual Meeting  
Lisbon, Portugal  
September 12 - 16 2011



# Presenter Disclosure

**Jerry R. Colca, PhD**

Board Member/Cofounder: **Metabolic Solutions Development Co., LLC**

Employee: **Metabolic Solutions Development Co., LLC**

Stock/Shareholder: **Metabolic Solutions Development Co., LLC**




47th EASD Annual Meeting  
Lisbon, Portugal  
September 12 - 16 2011

# Mechanism of Action for Insulin Sensitizers

**Old**

Troglitazone; Rosiglitazone; Pioglitazone

 **Original TZDs**



**PPAR-Driven Gene Changes**



**Fat Sequestered  
Increased Insulin Action  
Fluid Retention  
Weight Gain**

**New**

 **MSDC**


**Mito Target of TZDs (mTOT)**



MSDC-0160  
MSDC-0602

(Phase 2 clinical trials)

Metabolic signals




**Nuclear Regulatory Factors**

**Improved Insulin Action    Regeneration of Brown Fat  
Improved Lipid Profiles    Regeneration of  $\beta$ -cells**

# Relative Activity Against PPAR $\gamma$





PPAR $\gamma$  Binding



## This Presentation:

Compounds also stimulate brown-like phenotype in precursors from axillary fat pads and stimulate production and secretion of adiponectin in a PPAR $\gamma$ -independent manner.

# TZDs Increase Differentiation of Brown Fat Progenitors




- The effect of TZDs on BAT is maintained in new insulin sensitizers.
- Similar to pio and rosi (although > 30-fold, 10-fold reduction at PPAR $\gamma$  vs rosi, pio).
- Not blocked by PPAR $\gamma$  antagonists; signaling occurs in PPAR $\gamma$ -KO cells.


**Will new insulin sensitizers affect subcutaneous fat ?**  
**> Adiponectin production/secretion ?**

# Methods

- Progenitor cells are isolated from axillary fat pads from 3-4 week old CD-1 mice and cultured for 7 days in DMEM + 10% FBS.
- At 90% confluence the cells are treated with various concentrations of compounds (172 nM insulin); medium is changed every 48 hours with fresh additions.
- Cells are harvested for mRNA analysis (rt-PCR) and Western Blots at various time points.
- Conditioned medium is harvested for measurement of secreted adiponectin by ELISA .



- Pad isolated from 10-15 mice
- Digested with collagenase
- Precursors isolated and plated
- Grown to 90% confluence






# Conversion of Progenitor Cells to Brown-like Phenotype (7 days of treatment)

DMSO




MSDC-0160 (3  $\mu$ M)

Rosiglitazone (1  $\mu$ M)

10x




40x




- Multilocular fat droplets
- Increased Mitochondria
- Increased UCP1 (message and protein)
- Increased adiponectin (message, protein, and secretion)

# PPAR $\gamma$ Antagonists Do Not Block Compound-Induced Effects on UCP1

## UCP1- mRNA





Note: antagonists affect baseline UCP1 mRNA and differentiation in absence of compounds



and rosi action in a PPAR $\gamma$  cell assay

## UCP1- Western Blot




but do *not* block the effects of the compounds to increase UCP1 mRNA and protein.





# Increased Mitochondria in Subcutaneous Adipose Progenitors



CD-1 mice



MSDC-0160





C57 mice-  
PPAR $\gamma$  KO





**New Insulin sensitizers also increase mitochondrial biogenesis by a mechanism independent of PPAR $\gamma$  activation in SC adipose progenitors.**

# Increased Adiponectin Production and Secretion



Western blot

## Secretion



**New insulin sensitizers directly increase adiponectin production in subcutaneous adipose Independent of expansion of white fat or activation of PPAR $\gamma$ .**

# Summary

- **New insulin sensitizing agents cause browning of progenitor cells from the axillary fat pad in a PPAR-independent manner.**
  - Not related to ability to bind to and activate PPAR $\gamma$  - rosi vs 0160 and 0602
  - Not blocked by PPAR $\gamma$  antagonists
- **This mechanism includes increase in UCP1 and mitochondrial biogenesis.**
  - mRNA
  - Protein
- **The compounds increase adiponectin in a PPAR $\gamma$ -independent manner.**
  - Expression
  - Secretion into the medium

- ❖ New insulin sensitizers not only stimulate differentiation of dedicated brown fat progenitor cells but also favor brown adipose-like phenotype and increase adiponectin secretion from subcutaneous adipose.
- ❖ There is potential for a new generation of insulin sensitizing agents that avoids side effects associated with activation of PPAR $\gamma$ .

# Implications for Novel Agents

